Welcome to our dedicated page for AMRS news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on AMRS stock.
Amyris, Inc. (Nasdaq: AMRS) serves as a hub for tracking developments at the forefront of sustainable biotechnology. This resource aggregates official updates from the synthetic biology leader currently undergoing strategic restructuring while maintaining its commitment to transforming consumer markets through bioscience innovations.
Investors and industry observers will find comprehensive coverage of financial updates, leadership changes, and operational milestones. The collection includes press releases detailing AMRS's Chapter 11 restructuring progress, R&D advancements through its Lab-to-Market™ platform, and partnerships supporting its shift toward core biotechnology competencies.
Key content focuses on operational restructuring efforts, sustainability initiatives, and technology licensing agreements. Users can monitor updates about the company's consumer brand divestitures, cost optimization strategies, and ongoing supply chain relationships with global manufacturers.
Bookmark this page for streamlined access to verified AMRS communications, including regulatory filings and strategic partnership announcements. Check back regularly for the latest developments as Amyris positions itself for long-term stability in sustainable ingredient markets.
Amyris, Inc. (Nasdaq: AMRS) announced a new partnership with Jonathan Van Ness to launch a clean haircare brand, aiming to revolutionize the industry with sustainable, effective products. Expected to launch in summer 2021, the brand will utilize Amyris's proprietary hemi-squalane ingredient for enhanced hair health across all textures. This move expands Amyris's footprint in the clean beauty market, which represents a significant segment of the $300 billion beauty industry, furthering its commitment to inclusivity and environmentally friendly products.
Amyris, Inc. (Nasdaq: AMRS) announced its entry into the Greater China market with its Biossance Clean Beauty brand, partnering with SuperOrdinary Group. This collaboration positions Biossance within one of the fastest-growing beauty markets where consumers prioritize sustainable products. The partnership aims to leverage SuperOrdinary's expertise in establishing leading brands in China. Amyris expects significant growth, citing strong fourth-quarter sales and aiming for sales revenue equivalent to all of 2019. This strategic move aligns with the increasing demand for clean beauty products in China.
Amyris, Inc. (Nasdaq: AMRS) has achieved the Bonsucro Chain of Custody Certification, ensuring sustainable sugarcane supply chain practices from farmer to end user. This certification underscores Amyris' commitment to delivering clean and sustainable products in the Clean Health and Beauty sectors, aligning with ethical and fair-trade practices. CEO John Melo emphasized that consumer demand for sustainably sourced products has surged, further enhancing Amyris’ growth potential and strengthening partnerships. This makes Amyris a pioneer as the first biotech company to receive this certification, indicating significant industry differentiation.
Amyris, Inc. (Nasdaq: AMRS), a leader in synthetic biotechnology, has completed a strategic transaction with DSM Nutritional Products Ltd valued at $50 million. This deal involves licensing rights for Farnesene to Givaudan for a specialty ingredient. Of the total amount, $30 million is due by December 30, 2020, with further payments scheduled for the first quarter of 2021 and potential milestone payments thereafter. This is the first of three anticipated transactions as per management's recent investor event on December 15, 2020.
Amyris, a synthetic biotechnology firm listed on Nasdaq as AMRS, successfully hosted the first session of its virtual investor mini-series, titled "Delivering on the Promise of Synthetic Biology." This session, held on December 15, 2020, featured nearly 300 participants and included a business update, technology presentation, and Q&A. CEO John Melo discussed strategic transactions and future outlook, while SVP Sunil Chandran showcased the company's technology platform. Future sessions are planned, focusing on the Consumer and Ingredients portfolios in Q1 2021.
Amyris, in a recent announcement, revealed the launch of a virtual investor mini-series titled "Delivering on the Promise of Synthetic Biology". The first webinar, Science and Technology, Sustainable Solutions for a Healthier Planet, is scheduled for December 15, 2020, at 1:00 PM ET. The initiative aims to educate investors on Amyris's operations and advancements, particularly in sustainable ingredients for health and beauty markets. Future sessions will cover the Consumer and Ingredients portfolios, enhancing investor engagement.
Amyris, Inc. (Nasdaq: AMRS) reported record sales revenue from its consumer brands during Black Friday, with sales revenue tripling compared to 2019. The Biossance brand alone surpassed $1 million in sales, driven by a 129% increase in customers. Notably, 57% of sales came from first-time customers. Overall, Amyris's fourth quarter is expected to match its total sales from 2019. The company has invested in its digital infrastructure to meet rising online shopping demands, ensuring efficient supply chain and fulfillment capabilities.
Amyris, a leading synthetic biotechnology company based in Emeryville, California, will present at Evercore ISI's 3rd Annual HealthCONx Conference on December 3, 2020, at 2:40 p.m. ET. The presentation will highlight the company's innovations in sustainable and natural ingredients for Clean Health and Beauty markets. A live webcast and replay will be available on the company's Investor Relations website. Amyris is known for its three consumer brands: Biossance, Pipette, and Purecane, all built on its No Compromise promise of clean ingredients.
Amyris, Inc. (Nasdaq: AMRS) reported a strong Q3 2020, with Product Revenue reaching $31 million, up 58% year-over-year. Consumer sales surged by 203%, contributing to an expanded Gross Margin of 41%. Adjusted EBITDA improved to -$33 million, a $10 million enhancement from last year, as cash operating expenses decreased by 10% to $43 million. The company anticipates a profitable 2021, driven by successful strategic initiatives and high growth in consumer brands. However, the ongoing impact of COVID-19 adds uncertainty to the future financial outlook.
